MRSA infections are treated with a specific set of antibiotics that can bypass the resistance mechanism that makes standard options ineffective. The exact antibiotic depends on where the infection is and how severe it is. Mild skin infections are often managed with oral pills at home, while serious bloodstream or bone infections require IV antibiotics in a hospital.
Why Most Antibiotics Don’t Work on MRSA
MRSA produces a modified protein on its cell wall that most antibiotics can’t latch onto. Standard antibiotics like amoxicillin, cephalexin, and other common prescriptions work by binding to proteins involved in building the bacterial cell wall. MRSA’s version of this protein has a closed, guarded shape that prevents these drugs from attaching. This single change makes MRSA resistant to nearly all standard penicillins and cephalosporins, which is why treatment requires drugs that use different strategies to kill the bacteria.
Oral Antibiotics for Skin Infections
Most MRSA infections people encounter are skin and soft tissue infections: boils, abscesses, cellulitis, and wound infections. These are typically treated with one of three oral antibiotics.
Trimethoprim-sulfamethoxazole (Bactrim) is one of the most commonly prescribed options. The standard dose is one double-strength tablet twice daily for 7 to 15 days. Infectious disease guidelines give it a strong recommendation for MRSA skin infections, and studies show it works as well as the other oral choices. It’s inexpensive and widely available.
Doxycycline is another first-line choice, particularly useful when a patient can’t tolerate Bactrim. It belongs to the tetracycline family and works by blocking the bacteria’s ability to make proteins. It’s taken twice daily, and the typical course runs 7 to 14 days. Sun sensitivity is the most notable side effect.
Clindamycin is effective against many MRSA strains, but there’s a catch. Some MRSA bacteria carry a hidden resistance to clindamycin that only shows up under certain conditions. Labs can detect this with a D-zone test. In regions where inducible clindamycin resistance runs around 20% or higher, your provider may choose a different drug or specifically request this test. Clindamycin also carries a higher risk of causing a serious intestinal infection from C. difficile bacteria compared to the other oral options.
Vancomycin: The Standard IV Treatment
For serious MRSA infections like bloodstream infections, pneumonia, bone infections, or heart valve infections, vancomycin given intravenously has been the cornerstone treatment for decades. It works by a completely different mechanism than standard antibiotics, targeting a different step in the cell wall construction process that MRSA’s resistance doesn’t protect against.
Vancomycin requires careful blood level monitoring during treatment. Clinicians aim for a specific drug exposure target to balance effectiveness against kidney toxicity. Previous guidelines recommended keeping blood trough levels between 15 and 20 mg/L, but newer evidence suggests slightly lower targets (10 to 15 mg/L) may be equally effective while reducing the risk of kidney damage. Treatment courses for serious infections often run two to six weeks depending on the infection site.
Alternatives When Vancomycin Isn’t Enough
Some MRSA infections don’t respond to vancomycin, or patients can’t tolerate it. Several alternatives exist for these situations.
Daptomycin is an IV antibiotic that kills MRSA by punching holes in the bacterial cell membrane. It works well for bloodstream infections and skin infections, but it cannot treat pneumonia. Lung surfactant, the natural substance that keeps your air sacs open, physically inactivates daptomycin. This means it’s useless for any lung-based infection, regardless of how well it works elsewhere in the body.
Linezolid is notable because it comes in both IV and oral forms, which means patients can sometimes transition from hospital to home treatment without switching drugs. It works by blocking bacterial protein production at an early stage. The major concern with linezolid is a dangerous interaction with antidepressants and other psychiatric medications that affect serotonin levels. Combining linezolid with these drugs can cause serotonin to build up in the brain, leading to confusion, muscle twitching, fever, and in some reported cases, death. If you take an SSRI or similar medication, it typically needs to be stopped at least two weeks before starting linezolid (five weeks for fluoxetine, which stays in the body longer). Linezolid can also lower platelet counts with extended use, so blood monitoring is necessary for longer courses.
Tedizolid is a newer drug in the same class as linezolid. Its main advantages are a shorter treatment course (6 days versus 10 for linezolid) and once-daily dosing instead of twice daily. Clinical trials found it equally effective, with fewer gastrointestinal side effects: about 20% of patients experienced nausea, vomiting, or diarrhea compared to 25% with linezolid.
Newer and Specialized Options
Ceftaroline is the rare exception to the rule that MRSA resists all drugs in the penicillin and cephalosporin family. This fifth-generation cephalosporin uses a clever two-step mechanism. The first molecule binds to an alternate site on MRSA’s resistant protein, which forces the protein’s active site to open up. A second molecule then slips into that newly exposed site and shuts down cell wall production. No other commercially available drug in its class can do this. Ceftaroline is approved for skin infections and pneumonia, and it’s given intravenously.
Oritavancin is designed for situations where a patient needs treatment but follow-up is difficult. It’s given as a single 1,200 mg IV infusion that provides antibacterial activity for weeks due to its extremely long duration in the body. Some clinicians use a two-dose approach, with a second 800 mg infusion one week later, to extend coverage for more complicated infections. This makes it particularly useful for skin and soft tissue infections in patients who may not reliably return for daily treatment.
Telavancin is typically reserved for MRSA infections that have failed other treatments. It has shown strong results in patients with bloodstream infections that persisted through courses of both vancomycin and daptomycin. It carries a warning for kidney toxicity, which limits its use in some patients but is less of a concern for those already on dialysis.
How Infection Type Determines the Antibiotic
The location and severity of your infection narrows the choices significantly. A small skin abscess may only need drainage and a course of Bactrim. A deep wound infection might call for IV vancomycin for several weeks. A MRSA bloodstream infection requires IV treatment and close monitoring, often with vancomycin or daptomycin. Pneumonia eliminates daptomycin from consideration entirely, leaving vancomycin, linezolid, or ceftaroline as the primary options.
Resistance testing also plays a role. When a lab cultures your MRSA sample, they test it against multiple antibiotics to see which ones the specific strain is susceptible to. Resistance to erythromycin and clindamycin remains common across MRSA strains globally, while resistance to trimethoprim-sulfamethoxazole and doxycycline is less frequent, which is part of why those drugs remain reliable oral choices. Your treatment plan is ultimately shaped by what the lab results show your particular strain responds to, combined with where the infection is located and how sick you are.